Marengo to Present Late-Breaking Clinical Oral Abstract at SITC 2025 Highlighting Initial Monotherapy Activity of Invikafusp Alfa in Tissue-Agnostic, TMB-High Advanced Cancers

On October 31, 2025 Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and inflammation & immunology (I&I), reported that it will present a late-breaking oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2025 Annual Meeting, taking place November 5–9, 2025, in National Harbor, Maryland.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will include initial Phase 2 monotherapy results from the ongoing STARt-001 trial, which is evaluating Invikafusp alfa in tissue-agnostic, tumor mutational burden-high (TMB-H) advanced cancers. The findings underscore Invikafusp alfa’s potential to selectively activate unique T cell subsets, leading to reinvigoration of anti-tumor immunity across a broad range of solid tumors.

Presentation Details:

Title: Initial monotherapy clinical activity of invikafusp alfa, a first-in-class TCR β-chain-targeted bifunctional antibody, in tissue-agnostic, TMB-H patients from STARt-001, a Phase 1/2 trial
Conference: SITC (Free SITC Whitepaper) Annual Meeting 2025
Abstract Number: LBA1316
Session Title: Clinical Oral Abstract Session 1
Session Date and Time: Friday, November 7, 2025, 11:30 AM ET
Presenter: Aurélien Marabelle, MD, PhD (Gustave Roussy Cancer Center, France)
Marengo will also present data from its TriSTAR T cell engager platform in addition to four preclinical analyses in collaboration with the National Cancer Institute (NCI) exploring rational combinations of Invikafusp alfa with standard-of-care modalities.

(Press release, Marengo Therapeutics, OCT 31, 2025, View Source [SID1234659211])